FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA
Center | Date | Time | Location |
---|---|---|---|
CDRH | June 2, 2004 June 3, 2004 |
10 a.m. - 6 p.m. 8 a.m. - 5 p.m. |
Gaithersburg Marriott |
|
June 2: Agenda;
Roster;
Questions;
Briefing Information;
Transcript
| | June 3: Agenda; Hip Guidance Questions; Knee Reclassification Questions; Briefing Information; Transcript | |
Agenda:
On June 2, 2004, the committee will discuss, make recommendations, and vote
on a premarket approval application for an artificial lumbar disc intended for
spinal arthroplasty in skeletally mature patients with degenerative disc disease
at one level from L4-S1.
On June 3, 2004, from 8 a.m. to 1 p.m., the committee will discuss, make recommendations, and vote on a reclassification petition for total and unicompartmental mobile bearing knee joint prostheses. Also on June 3, 2004, from 1 p.m. to 5 p.m., the committee will discuss and make recommendations on a draft guidance document for clinical performance data requirements for hip joint prostheses. The draft guidance document is available at: http://www.fda.gov/ohrms/dockets/dailys/04/apr04/040504/03n-0561-c00001-vol2.pdf.
Background material and meeting information
will become available no later than the day before the meeting (Simply select
the appropriate committee link).
NOTE: Material for the June 2 session will be posted June 1, 2004. Material
for the June 3 session will be posted June 2, 2004.
Procedure:
Interested persons may present data, information, or views, orally or in writing,
on issues pending before the committee. Written submissions may be made to the
contact person by May 18, 2004. On June 2, 2004, oral presentations from the
public will be scheduled for approximately 30 minutes at the beginning of committee
deliberations and for approximately 30 minutes near the end of the deliberations.
On June 3, 2004, oral presentations from the public will be scheduled between
approximately 8:15 a.m. and 8:45 a.m. and 1:15 p.m. and 1:45 p.m.. Time allotted
for each presentation may be limited. Those desiring to make formal oral presentations
should notify the contact person before May 18, 2004, and submit a brief statement
of the general nature of the evidence or arguments they wish to present, the
names and addresses of proposed participants, and an indication of the approximate
time requested to make their presentation. Persons attending FDA's advisory
committee meetings are advised that the agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee meetings
and will make every effort to accommodate persons with physical disabilities
or special needs. If you require special accommodations due to a disability,
please contact AnnMarie Williams at 301-594-1283, ext. 113, at least 7 days
in advance of the meeting.
Contact Person:
Janet L. Scudiero, Center for Devices and Radiological Health
(HFZ-410), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD
20850, 301-594-1184, ext. 176, or FDA Advisory Committee Information Line, 1-800-741-8138
(301-443-0572 in the Washington, DC area), code 3014512521. Please call the
Information Line for up-to-date information on this meeting.
[ Full
FR Notice ]